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ABSTRACT
Objectives: To compare the efficacy of a proactive
approach with a reactive approach to offer intensive
smoking cessation intervention using motivational
interviewing (MI).
Design: Before–after comparison in 2 academic
hospitals with parallel comparisons in 2 control
hospitals.
Setting: Academic hospitals in Switzerland.
Participants: Smokers hospitalised for an acute
coronary syndrome (ACS).
Intervention: In the intervention hospitals during the
intervention phase, a resident physician trained in MI
systematically offered counselling to all smokers
admitted for ACS, followed by 4 telephone counselling
sessions over 2 months by a nurse trained in MI. In
the observation phase, the in-hospital intervention was
offered only to patients whose clinicians requested a
smoking cessation intervention. In the control
hospitals, no intensive smoking cessation intervention
was offered.
Primary and secondary outcomes: The primary
outcome was 1 week smoking abstinence (point
prevalence) at 12 months. Secondary outcomes were
the number of smokers who received the in-hospital
smoking cessation intervention and the duration of the
intervention.
Results: In the intervention centres during the
intervention phase, 87% of smokers (N=193/225)
received a smoking cessation intervention compared to
22% in the observational phase (p<0.001). Median
duration of counselling was 50 min. During the
intervention phase, 78% received a phone follow-up
for a median total duration of 42 min in 4 sessions.
Prescription of nicotine replacement therapy at
discharge increased from 18% to 58% in the
intervention phase (risk ratio (RR): 3.3 (95% CI 2.4 to
4.3; p≤0.001). Smoking cessation at 12-month
increased from 43% to 51% comparing the
observation and intervention phases (RR=1.20, 95% CI
0.98 to 1.46; p=0.08; 97% with outcome assessment).
In the control hospitals, the RR for quitting was 1.02
(95% CI 0.84 to 1.25; p=0.8, 92% with outcome
assessment).
Conclusions: A proactive strategy offering intensive
smoking cessation intervention based on MI to all
smokers hospitalised for ACS significantly increases
the uptake of smoking cessation counselling and might
increase smoking abstinence at 12 months.
INTRODUCTION
Cardiovascular disease (CVD) is the leading
cause of death in adults in the USA and in
Strengths and limitations of this study
▪ Four university centres were involved with two
centres serving as a parallel comparison.
▪ Smoking cessation outcome assessed after
12 months in 97% of participants in the inter-
vention centres.
▪ The weaker before–after design with parallel
comparisons limits causal inference of the
potential effects of the intervention.
▪ There were significant differences in attendance
rates to cardiac rehabilitation and length of stay
between the observation and intervention phase,
limiting the interpretation of the findings.
▪ Participants received phone counselling after
their hospital stay in the intervention phase, but
not in the observation phase, thereby inherently
limiting the interpretation of the comparison
between a proactive and a reactive approach of
offering a smoking cessation intervention on
smoking cessation rates at 12 months.
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Europe and smoking is the leading cause of CVD.1
Smokers who quit after a myocardial infarction can
expect a 36% reduction in CVD mortality over 2 years
compared with continuing smokers.2 3 In a meta-analysis
of randomised controlled trials (RCTs) of smokers hos-
pitalised for a CVD diagnosis, smoking cessation inter-
ventions started in the hospital and sustained in the
ambulatory setting for at least 1 month after discharge,
increased smoking cessation rates by more than 40%.4 5
While the effectiveness of smoking cessation counsel-
ling interventions and their components has been exten-
sively studied, the optimal delivery of smoking cessation
interventions has been less studied.6 7 Current guide-
lines promote the use of the 5A’s for the delivery of
smoking cessation interventions where healthcare provi-
ders assist smokers willing to make a quit attempt after
having assessed their ‘readiness to quit’.8 9 However, past
negative experiences with healthcare workers, where
smokers felt to be negatively judged because of their
behaviour, may impact their willingness to explore their
habit with a counsellor.10–12 The Clinical Practice
Guideline for Treating Tobacco Use and Dependence
recommends the use of motivational interviewing (MI)
with smokers who express low motivation to quit.13 MI is
a collaborative, person-centred guidance to elicit and
strengthen motivation to change; MI could allow
approach all smokers, regardless of their self-reported
motivation to quit smoking.14 15 While a recent study
showed promising results on increasing the uptake of
smoking cessation interventions when systematically
identifying and assisting hospitalised smokers, 30%
declined consent to participate in the study and an
additional 30% of those offered behavioural support
refused it.16
Our primary aim was to test the efﬁcacy of a proactive
approach compared with a reactive approach to offer
intensive smoking cessation intervention using MI to
smokers hospitalised for an acute coronary syndrome
(ACS) in two sites in a before–after comparison. We also
aimed at making a parallel comparison of the smoking
cessation rates of smokers hospitalised in these interven-
tion sites to the quit rates of smokers hospitalised in two
other sites without intensive smoking cessation interven-
tion throughout the study duration.
MATERIALS AND METHODS
Study population
The study population comprised smoking participants to
the SPUM ACS (Special Program University Medicine -
Acute coronary Syndrome) cohort study; a national
cohort of patients with ACS conducted in four academic
hospitals in Switzerland and registered at clinicaltrials.
gov (NCT 01000701 and NCT 01075867).17–19 Inclusion
criteria were patients aged 18 years or older presenting
with the principal diagnosis of ST segment-elevation
myocardial infarction (STEMI), non-STEMI (NSTEMI)
or unstable angina (UA), actively smoking at the time of
inclusion and willing to participate in a clinical study
including a follow-up examination at 12 months. Active
smoking was deﬁned as smoking one cigarette or more
per day during the month preceding the hospital stay.
Exclusion criteria were index revascularisation with coron-
ary artery bypass graft, severe physical disability, inability
to give consent (dementia), impossibility of returning for
a follow-up clinical visit at 12 months and <1 year of life
expectancy for non-cardiac reasons. Patients were fol-
lowed at 12 months for assessment of smoking cessation
outcomes (ﬁgure 1). The observation phase was from
August 2009 to October 2010 and the intervention phase
from November 2010 to February 2012. The study
includes two intervention sites (A and B) and two control
sites (C and D). There are ﬁve major academic medical
centres in Switzerland and four participated in the pro-
spective cohort study of patients with ACS.17–19 The two
intervention sites were chosen based on the existence of
a team providing smoking cessation interventions to hos-
pitalised smokers before the start of the study on a react-
ive basis. There was no random allocation of study sites
into control and intervention sites. Detailed documenta-
tion of the ﬂow of participants from the arrival to the
emergency room for suspected ACS to the inclusion in
the clinical follow-up study was performed in study site A
(see online supplementary appendix).
Study design
The study design is a multicentre before–after study with
parallel group comparisons. We made two comparisons
for smoking cessation outcomes at 12 months follow-up
and process outcomes: a before–after comparison
between observation and intervention phases in inter-
vention sites A and B; a parallel group comparison
between intervention (A and B) and control (C and D)
sites in both observation and intervention phases.
Study protocol and interventions
During the observation phase at the intervention sites
(study sites A and B), the standard practice in place was
that patients received information about the possibility
of a dedicated smoking cessation intervention and clini-
cians in charge of patients could request a specialised
smoking cessation intervention for hospitalised smokers
through a simple phone call and after patient’s agree-
ment.20 21 We called this approach a ‘reactive approach’
to delivering smoking cessation interventions. In the
intervention phase, a resident physician trained in MI
identiﬁed all smokers included in the clinical follow-up
study and systematically approached them to get permis-
sion to discuss their smoking habit. We called this
approach a ‘systematic approach’ to delivering smoking
cessation interventions. There was no restriction on the
duration of the interview and residents ended the discus-
sion once they felt an increase in the resistance of the
patients, if they were interrupted by competing care to
patients or if patients speciﬁcally asked the interview to
end. Multiple MI sessions were allowed during the
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hospital stay and at the end of each session, the resident
systematically offered the possibility of additional consul-
tations during the hospital stay provided the logistics
were possible. While the in-hospital counselling interven-
tion was the same in the observation and in the interven-
tion phase, residents also systematically suggested to
patients to be contacted by a study nurse after their hos-
pital stay for four ambulatory telephone contacts during
the intervention phase, which was not done in the obser-
vation phase. Study nurses systematically contacted by
phone each patient at 2 days, 1 week, 1 month and
2 months after discharge from the acute care hospital.4
Whenever possible, the nurse tried to meet all coun-
selled smokers for a brief face-to-face encounter before
discharge. In addition to training in tobacco cessation
counselling and prescription of nicotine replacement
therapy (NRT),21 residents were trained in MI during
four sessions of 4 hours each over 1 month separated by
1 week before the intervention phase. To allow residents
to adapt the interview to the patient’s needs, we did not
develop a detailed manual for directing the MI.22 To min-
imise interference with the intervention, most data were
collected during the inclusion of patients before the resi-
dents approached patients. If not already prescribed by
the health care provider (HCP) in the ward, the resident
offered NRT and brochures on smoking cessation.
Residents provided the HCP in charge of the patient with
a brief summary of the intervention and recommenda-
tions for NRT and sent a medical report to the patient’s
primary care provider. Study nurses followed the same
training in MI as the residents. NRT, which is not reim-
bursed in Switzerland, was available free of charge during
the hospital stay, but were at the patients’ charge in
ambulatory care. In the control study sites (C and D),
there was no dedicated smoking cessation intervention
throughout the study duration and participants received
minimal smoking cessation advice by hospital clinicians
in charge of their care.
Covariates
Current smoking status, age of smoking initiation and
daily cigarettes consumption were assessed for all patients
throughout the study duration in all sites during the
inclusion process in the clinical study. In the intervention
sites during the intervention phase, patients were given a
questionnaire to be ﬁlled during the hospital stay.
Administrative (length of stay, discharge home or
direct transfer to a peripheral hospital or to cardiovascu-
lar rehabilitation (CR)), demographic (age, sex, race,
education), medical (type of ACS (NSTEMI/UA and
STEMI); previous coronary health disease (CHD)) data
and processes of care were collected during the inclu-
sion in the clinical follow-up study and completed after
discharge. Attendance rate to CR and type of CR (ambu-
latory vs hospital) were assessed from administrative data
available at discharge and from self-report during the
ambulatory follow-up visit at 1 year. In Switzerland,
healthcare providers’ organise CR during the hospital
stay or provide patients with information to beneﬁt from
CR. Thus patients could be directly addressed to an
inpatient CR facility or attend ambulatory CR in the out-
patient setting. Quality indicators were based on cardio-
logical guidelines and included systematic collection of
reason for non-prescription for preventive medication.17
Outcomes
The primary outcome for smoking cessation was 1 week
smoking abstinence (point prevalence) at 12 months. At
the time of inclusion, patients were informed that they
would be asked about their smoking status during a visit
at 12 months. Self-reported smoking cessation was bio-
chemically conﬁrmed by exhaled carbon monoxide
levels (Micro Smokerlyzer; Bedfont Scientiﬁc) at the
1-year follow-up visit in all sites.23 Patients who did not
return at 12 months were contacted either by phone or
mail. We classiﬁed those with carbon monoxide levels of
at least 10 ppm as current smokers. Secondary process
outcomes were: the number of patients who received
smoking cessation counselling, NRT at discharge and
follow-up as well as the duration and number of inter-
ventions during the hospitalisation and follow-up.
Statistical analysis
Frequencies, means with SDs and medians with IQRs
were used when appropriate, as were χ2 tests, Fisher’s
exact test, Wilcoxon rank-sum test and analysis of vari-
ance (ANOVA) for bivariate analyses. The primary ana-
lysis examined the point estimate and 95% CI of the risk
ratio (RR) for smoking cessation at 12 months between
both phases in the intervention sites and using an
intention-to-treat approach. The sample size calculation
was based on an expected 10% absolute increase in
Figure 1 Study design. Before–after intervention with parallel group comparisons: we compared the 7 days point smoking
prevalence at 12 months follow-up between participants included in the reactive versus the proactive intervention phases in
intervention sites (A and B). We also compared the 7 days point smoking prevalence at 12 months follow-up between participants
included during the same period in observation sites (C and D).
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smoking abstinence at 12 months in the two interven-
tion centres. The 10% difference was based on a
summary estimate of 11 previous RCTs identiﬁed in a
systematic review and meta-analysis which included
smokers hospitalised with CHD and tested the effect of
a high-intensity intervention with phone follow-up.5 24–36
The summary quit rate over all these studies in the inter-
vention groups was 45% and 31% in the control groups,
thus an absolute risk difference (ARD) of 14%. Using
an α-level of 0.05 and a power of 80%, and given the
potential increase in abstinence due to the intervention
in some smokers in the observation phase, we estimated
that 400 patients had to be included in the intervention
sites (A and B) over the entire study period to detect a
10% absolute difference in quit rates. Secondary ana-
lyses were a comparison of the smoking cessation rates
at 12 months between both phases in the control study
sites (C and D; ﬁgure 2). The study was not powered to
detect a signiﬁcant difference between intervention and
control sites over the observation and intervention
phases. We also conducted stratiﬁed analyses by attend-
ance to CR and education status (with or without univer-
sity degree). We further tested the association between
the presence and duration of counselling between
phases using logistic regression models and Poisson
logistic regression models. Statistical signiﬁcance was set
at 0.05. All analyses were performed using STATA V.12
(StataCorp, College Station, Texas, USA).
RESULTS
Study population
Between August 2009 and February 2012, 616 patients
admitted for ACS were included in the clinical follow-up
study in site A, and 510 in site B. A total of 458 (40%)
were current smokers and included in the subsequent
analyses (ﬁgure 2 and online supplementary appendix
ﬁgure 1). At 12 months follow-up, smoking status was
assessed in 97% while 15 participants had died (ﬁgure 2
and online supplementary appendix ﬁgure 1). In the
study sites C and D, 192 smokers were included in the
observation phase and 244 in the intervention phase
(ﬁgure 2 and online supplementary appendix table 1).
At 1 year follow-up, smoking status was obtained for 92%
while 12 participants died.
Mean age of participants included in the intervention
sites (study sites A and B) in the intervention phase was
55 years, 20% were women and 52% had been hospita-
lised for STEMI (table 1). There were no signiﬁcant dif-
ferences in baseline characteristics between participants
in observation and intervention phases, except for the
longer stay of patients directly discharged home.
Process outcomes
In the intervention sites (study sites A and B), 22% of
patients received intensive smoking cessation counselling
during the observation phase compared to 87% in the
intervention phase (ﬁgure 2 and table 2). Among the
13% who did not receive counselling in the intervention
phase, 10% (n=24) were transferred to another facility
or discharged home before the counsellor could
approach them; 2% (N=4) completely refused to discuss
with counsellor and 1% (N=2) had a major language
barrier. The median duration of the intervention during
the hospital stay was 50 min and did not signiﬁcantly
vary between both phases. During the intervention
phase, 78% received a phone follow-up (90% of those
receiving in-hospital counselling) for a total median dur-
ation of 42 min in four sessions. Prescription of NRT at
Figure 2 Flow chart of participants included in the intervention sites (A and B) and control sites (C and D) during observation
phase (August 2009–October 2010) and intervention phase (November 2010–February 2012). Intensive smoking cessation
counselling was offered during the observation phase in the observation on request and systematically during the intervention
phase. Phone follow-up was only offered in the intervention phase in the intervention sites (see Materials and methods section).
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discharge increased signiﬁcantly from 18% to 58% in
the intervention phase (RR: 3.3 (95% CI 2.4 to 4.3;
p≤0.001). Of those who received phone follow-ups in
the intervention phase, 67% were prescribed NRT at dis-
charge, but only 41% were still taking NRT at the ﬁrst
phone follow-up 2 days after discharge.
In the intervention sites, the proportion reporting
having attendedCR signiﬁcantly increased during the
intervention phase in the intervention sites from 58% to
73% (p<0.01). The proportion attending ambulatory CR
compared to hospital-based CR increased from 55% in
the observation phase to 67% in the intervention phase.
Smoking abstinence at 12 months
In the intervention sites, validated 12 months smoking
abstinence increased from 43% during the observation
phase to 51% in the intervention phase (RR 1.20; 95%
CI 0.98 to 1.46, p=0.08; ARD 8%, table 3). In the control
sites, 47% quit smoking in the observation phase com-
pared to 48% in the intervention phase (RR: 1.02 (95% CI
0.84 to 1.25; p=0.8; absolute risk reduction (ARR) 1%).
In exploratory stratiﬁed analyses comparing cessation
rates in intervention sites between both phases, the
apparent beneﬁt was mostly seen in those not attending
CR and those without university degree (table 3).
DISCUSSION
In this multicentre study involving smokers hospitalised
for an ACS, a systematic smoking cessation intervention
sharply increased the number of patients exposed to MI
and NRT. The median duration of counselling during
the hospital stay was 50 min and did not vary between
phases. Comparing observation with intervention
phases, the smoking abstinence at 1 year increased from
43% to 51% (8% absolute difference in abstinence,
Table 1 Baseline characteristics of participants hospitalised for an acute coronary syndrome in two academic hospitals
(intervention sites, study sites A and B) in Switzerland in the observation phase (August 2009–October 2010) and intervention
phase (November 2010–February 2012)
Intervention sites (A and B)
Observation phase Intervention phase
n=233 n=225 p Value
Demographic variables
Age, years (mean±SD) 57±11 55±11 0.06
Female, n (%) 46 (20) 45 (20) 0.9
Education, less than university degree, n (%)* 203 (88) 185 (83) 0.1
Living alone 68 (29) 55 (24) 0.3
Working status, employed, n (%) 136 (59) 143 (64) 0.3
Previous CHD, n (%) 46 (20) 37 (16) 0.3
Smoking variables
Cigarettes per day (median, Q1, Q3) 20 (10, 25) 20 (10, 25) 0.5
Age at smoking start (mean±SD) 19±6 18±6 0.6
Clinical variables
ACS-type:
STEMI (vs NSTEMI/UA), n (%) 121 (52) 116 (52) 0.9
Hospital stay
Length of stay, median (Q1, Q3), in days
For patients directly discharged home 5 (3,6) 5 (4,7) 0.04
For patients transferred to peripheral hospital 1 (0.5, 1) 1 (0.5, 2) 0.3
Treatment at discharge
Destination at discharge, n (%)
Home 148 (64) 138 1)
Direct transfer to cardiac rehabilitation 47 (20) 39 (17) 0.3
Transfer to peripheral hospital 36 (16) 47 (21)
Prescription of all recommended drug therapy at discharge† 222 (95) 216 (96) 0.6
Attendance to cardiovascular rehabilitation assessed at discharge
and 12 months follow-up (n, %)‡
136 (58) 163 (73) <0.01
Ambulatory vs stationary§ 74 (56) 109 (67) 0.05
*Six participants with missing information on education status or who refused to disclose their education status.
†Concomitant prescription at discharge unless contraindicated or not indicated for aspirin, clopidogrel/prasugrel or ticagrelor if percutaneous
coronary intervention (PCI) - stent treatment, β-blocker, statin, angiotensin-converting-enzyme inhibitor (ACEI) if LVEF ≤40%. When
participants transferred to peripheral hospital, β-blocker and ACEI/angiotensin receptor II antagonist (ATII) coded as not applicable.
‡Both ambulatory and stationary cardiovascular rehabilitation are covered after an ACS in Switzerland. Attendance rate computed using data
on direct referral to in-patient CR and on self-reported attendance at 1 year follow-up in order to capture information on those directly
transferred to a stationary CR and those attending CR in the ambulatory setting.
§Three participants with missing information on type of CR.
CHD, coronary heart disease; CR, cardiac rehabilitation; LVEF, left ventricular ejection fraction; n, number of participants; NSTEMI, non-ST
segment elevation myocardial infarction; Q1, first quartile; Q3, third quartile; STEMI, ST segment elevation myocardial infarction.
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p=0.08). At sites without dedicated in-hospital smoking
cessation intervention during the entire study period, no
difference in smoking abstinence was observed. In sub-
group analyses, the beneﬁt of the systematic intervention
appeared limited to smokers not attending CR and
those with lower education level.
Murray et al16 recently tested the effectiveness of sys-
tematically providing support to all identiﬁed smokers in
a RCT randomising medical wards in one medical
centre in the UK. The systematic identiﬁcation
permitted to increase the offer of behavioural support
from 46% to 100% of smokers and the acceptance of
behavioural support from 29% to 70% of smokers.
However, of the 1072 smokers identiﬁed in ward, 30%
declined consent to participate in the study and an add-
itional 30% of those offered behavioural support refused
it. In our study, detailed analysis of the ﬂow of partici-
pants until inclusion in the clinical study showed that
4% refused to enter the clinical follow-up study, followed
by 2% who completely refused to open the discussion
Table 2 Process outcomes in intervention sites (study sites A and B) comparing smokers hospitalised in the observation
phase (August 2009–October 2010) and intervention phase (November 2010–February 2012)
Observation
phase
Intervention
phase Risk ratio (95% CI)
or coefficient*
p
Value†N=233 N=225
Received intensive counselling during hospital stay (n, %) 52 (22) 193 (87)‡ 3.9 (3.0 to 5.0) <0.001
Duration of in-hospital counselling per participant in minutes
(median, Q1, Q3)
45 (45, 48) 50 (35, 60) 2.6 (−3.7 to 8.7) 0.4
Number of in-hospital counselling sessions
(median, min, max)
1 (1,2) 1 (1, 3) 0.15 (−0.15 to 0.45) 0.3
Received phone follow-up (n, %) NA 175 (78) – –
Duration of each phone follow-up in min (median, Q1, Q3) NA 11 (8, 17) – –
Total duration of phone follow-up in min (median, Q1, Q3) NA 42 (30, 61) – –
Number of phone follow-ups (median, Q1, Q3) NA 4 (3, 4) – –
Prescribed nicotine replacement therapy at discharge (n, %) 42 (18) 132 (59) 3.3 (2.4 to 4.3) <0.001
*Risk ratio and 95% CI calculated for dichotomous outcomes. Coefficients for duration of counselling obtained by linear regression. For
number of counselling sessions, coefficient obtained by Poisson logistic regression model.
†p Value calculated by χ2 for dichotomous outcomes (eg, proportion receiving counselling) and linear regression for duration of encounters.
‡Of the 13% who did not receive an intervention, 24 (11%) were transferred to another facility or discharged home before the counsellor
could approach them, 2% (n=4) completely refused to discuss with counsellor, 1% (n=2) were in a confused state.
CHD, coronary heart disease; CR, cardiac rehabilitation; LVEF, left ventricular ejection fraction; min, minutes; n, number of participants; NA,
not-applicable; NSTEMI, non-ST segment elevation myocardial infarction; Q1, first quartile; Q3, third quartile; STEMI, ST segment elevation
myocardial infarction.
Table 3 Smoking cessation outcomes at 12 months follow-up comparing participants in observation phase (August 2009 to
October 2010) and intervention phase (November 2010 to February 2012) at four university sites in Switzerland. Seven-day
point prevalence abstinence, validated by exhaled carbon monoxide*
N total for
analysis
Per cent of
quit in obs.
phase/interv.
phase
Risk ratio
(95% CI)
Absolute risk
difference
(%)
p
Value
Main outcome
Intervention sites (study sites A and B) (n=458) 443 42.0/50.2 1.20 (0.98 to 1.47) 8.3 0.08
Control sites (study sites C and D) (n=436) 428 46.8/47.8 1.02 (0.84 to 1.25) 1.1 0.8
Secondary analyses for participants in intervention sites (study sites A and B) (n=440)
Cardiac rehabilitation
With cardiac rehabilitation 296 51.5/53.7 1.04 (0.84 to 1.30) 2.2 0.7
No cardiac rehabilitation 143 29.5/43.6 1.48 (0.95 to 2.30) 14.1 0.09
Education status
University degree 64 59.3/51.3 0.87 (0.56 to 1.34) −7.9 0.5
No university degree 371 40.7/50.8 1.24 (1.0 to 1.6) 10.1 0.05
*Participants lost to follow-up or who withdrew consent (n=11, 97% follow-up rate) considered as smokers for these analyses. Participants
who died (n=15) during follow-up excluded from these analyses. Validated smoking cessation by carbon monoxide (CO) in 68% of quitters in
intervention sites and 40% of quitters in control sites. Two participants reported having quit during last 7 days despite a CO level of more than
10 ppm considered as smokers.
N, number of participants.
6 Auer R, et al. BMJ Open 2016;6:e011520. doi:10.1136/bmjopen-2016-011520
Open Access
group.bmj.com on October 24, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
with the resident approaching them to start a motiv-
ational interview. The beneﬁts of counselling all smokers
regardless of their motivation to quit using MI had also
previously been tested in a rigorously performed RCT in
1996–1997.29 Of the 164 smokers with acute myocardial
infarction, 8 (5%) refused to participate in the smoking
cessation intervention including follow-up at 6 months.
The smoking cessation rate at 1 year was 34% in the
observation group and 55% in the intervention group
(p<0.005). However, the study was performed in a single
study site and the rate attending CR was not provided
and is expectedly lower than the rate in our population,
thus limiting the comparison.
The sharp increase in uptake of the smoking cessation
intervention highlights the effect of changes in the
choice architecture described in behavioural economic
theories. Setting the default option from an opt-in to an
opt-out has been shown to be a powerful driver of uptake
in interventions.37 38 In the context of our study, the sys-
tematic offer of a smoking cessation intervention is
similar to an opt-out policy where patients ask not to have
the intervention compared to the opt-in policy where
patients or their caregivers speciﬁcally have to request a
smoking cessation intervention.
In our study, the rate discharged to CR in the inter-
vention sites increased from 58% to 73% between the
observation and intervention phases. Given that CR
includes smoking cessation counselling and support, it
could be considered a follow-up intervention as recom-
mended by guidelines and might be explained by a
higher attendance rate to CR.4 However, in stratiﬁed
analyses by attendance to CR, the beneﬁt of the system-
atic smoking cessation intervention was mostly apparent
among participants not attending CR. The systematic
approach might permit to counsel those most at risk of
lack of follow-up in the ambulatory care. The high
attendance rate to CR overall in our study might explain
the negative ﬁndings on smoking cessation rates over
follow-up39–42 Overall, attendance rates in the USA
range from 14% to up to 55%.39–42 We based our
sample size estimation on previous studies on smoking
cessation after ACS where attendance rates to CR were
expectedly lower. Unfortunately, we are unable to
compare the attendance rates in our study to previous
smoking cessation studies because previous studies
included in the Cochrane systematic review and to the
recent study by Murray et al16 have not reported on rates
of ambulatory CR.5 24–36 Future studies should also
better describe the concomitant interventions in the
ambulatory care in order to facilitate the interpretation
and translation of ﬁndings into clinical practice.
Our ﬁndings challenge the recommendation of allo-
cating high intensity counselling only to those ‘willing to
make a quit attempt’ recommended in smoking cessa-
tion guidelines based on the 5A’s framework.9
According to MI, motivation occurs in the interpersonal
context, which depends on the style used by counsellors
with smokers and may inﬂuence the acceptance rates of
the intervention.14 A previous rigorously performed
RCT including only those willing to make a serious quit
attempt was unable to show a beneﬁt on smoking
cessation.27
We found that the systematic smoking cessation inter-
vention led to an increase in NRT prescriptions at dis-
charge comparing the observation and intervention
phase at the intervention study sites. However, the high
cost of NRT after discharge, given that NRTs are not
covered by healthcare insurance companies in the
ambulatory setting in Switzerland, might explain the
lower rate of participants still taking NRT at the phone
follow-up. Future studies should test the effect of remov-
ing potential ﬁnancial barriers for using NRT after the
hospital stay on smoking cessation outcomes.
Our study has certain limitations. The weaker before–
after design with parallel group comparisons does limit
the causal inferences from our results. Participants
received phone counselling after their hospital stay in
the intervention phase, but not in the observation
phase. A systematic review on the beneﬁts of smoking
cessation intervention for hospitalised smokers suggested
that only interventions including a follow-up interven-
tion in the ambulatory setting have shown an effect on
smoking cessation outcomes at 12 months. This strongly
limits the comparison of smoking cessation rates
between the observation and intervention phase as the
smoking cessation increase could be due to either
phone follow-up or a proactive versus reactive approach
of offering smoking cessation intervention. We urge for
careful interpretation of the results given differences in
covariates between participants included in the observa-
tion phase and intervention phase (table 1). In the par-
ticipants included in the intervention sites, we found a
signiﬁcant increase in length of stay in addition to the
previously discussed increase in attendance rates to CR
between the observation and intervention phase.
Smoking cessation rates at 12 months were based on self-
report. We validated the 1 week smoking abstinence by
measuring the exhaled carbon monoxide whenever pos-
sible.23 However, misclassiﬁcation of the smoking cessa-
tion outcome is still possible. Rates of referral to CR
were based on information at discharge and self-report
at 1 year follow-up. The reliability of self-reported CR
referral has been validated in patients after an ACS in
Canada and used recently to report on enrolment rate
to CR in the USA.42 43 Exploratory subgroup analyses on
the differential effect of education level and attendance
to CR should be carefully interpreted, as these analyses
were deﬁned a posteriori. Patients were included in four
high-quality academic hospitals and results may not
apply to different settings. The MI sessions were not
recorded and the quality of interactions can therefore
not be directly assessed. We did not develop a detailed
manual for directing the MI. A prior meta-analysis sug-
gested that clinical trials in which MI was delivered
without a manual had showed better treatment
outcomes.22
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CONCLUSIONS
In summary, we found that a systematic smoking cessation
intervention using MI for smokers hospitalised for an ACS
compared to a reactive strategy relying on busy healthcare
providers to contact a specialised smoking cessation con-
sultation permitted to sharply increase the number of
patients counselled. In exploratory subgroup analyses of
data collected in one study centre, patients with lower edu-
cation level and not attending CR appeared to be more
likely to beneﬁt from the intervention. Comparison of
smoking cessation rates at 12 months between the observa-
tion and intervention phases are limited by the study
design and showed a trend towards an increase in smoking
cessation rates. Future studies should evaluate the beneﬁt
of systematically exposing smokers to a smoking cessation
intervention based on MI.
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